Suppr超能文献

[TREATMENT OPTIONS FOR DIABETIC MACULAR EDEMA].

作者信息

Berco Efraim, Rappoport Daniel, Pollack Ayala

机构信息

Ophthalmology Department, Kaplan Medical Center, Rehovot.

Hadassah and Hebrew University Medical School, Jerusalem.

出版信息

Harefuah. 2017 Feb;156(2):109-113.

Abstract

Diabetic retinopathy (DR) is the leading cause of vision loss in people under 65 years of age. Diabetic macular edema (DME) is the most common cause of moderate visual impairment in individuals with DR. Until recently, focal or grid laser photocoagulation has been the standard of care for DME. Laser photocoagulation has been shown to stabilize vision and prevent moderate vision loss. Recent studies on the effect of anti-vascular endothelial growth factor (VEGF) substances in DME, showed resolution of the edema and visual acuity gain. Thus, anti-VEGF therapy has become the first line of treatment for DME. Intravitreal steroids, also play a role in the management of DME, particularly in refractory cases, due to their antiinflammatory effect. This review focuses on the emerging treatment options in the management of DME.

摘要

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验